<DOC>
	<DOCNO>NCT00816660</DOCNO>
	<brief_summary>The objective study evaluate immediate tolerability safety rVWF : rFVIII subject Type 3 Von Willebrand Disease administration various dosage VWF : RCo .</brief_summary>
	<brief_title>Pharmacokinetic , Safety Tolerability Study Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex Type 3 Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Von Willebrand Disease , Type 3</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subject voluntarily give write informed consent ( conduct studyrelated procedure ) The subject hereditary type 3 VWD ( &lt; = 3 IU/dL VWF : Ag ) severe type 1 type 2A VWD ( VWF : RCo &lt; = 10 % FVIII : C &lt; 20 % ) The subject medical history least 25 exposure day VWF/FVIII coagulation factor concentrate The subject Karnofsky score &gt; = 70 % The subject 18 60 year age ( day signing informed consent ) NOT APPLICABLE IN ITALY : Female subject childbearing potential must negative pregnancy test agree practice contraception use method proven reliability day screen study completion visit APPLICABLE ONLY IN ITALY : Female subject childbearing potential must negative pregnancy test agree practice nonhormonalbased contraception use method proven reliability ( IUD acceptable ) day screen 96 hour last investigational drug infusion NOT APPLICABLE IN ITALY : The subject must agree therapy ( hormonebased contraception acceptable ) interfere coagulation factor pharmacokinetics 96 hour last investigational drug infusion APPLICABLE ONLY IN ITALY : The subject must agree therapy interfere coagulation factor pharmacokinetics 96 hour last investigational drug infusion The subject diagnose hereditary acquire coagulation disorder VWD ( include qualitative quantitative platelet disorder and/or international normalize ratio ( INR ) &gt; 1.4 ) The subject diagnose ADAMTS13 deficiency le 10 % ADAMTS13 activity The subject history presence VWF inhibitor The subject history presence FVIII inhibitor titer &gt; = 0.4 BU ( Nijmegen assay ) &gt; = 0.6 BU ( Bethesda assay ) The subject know hypersensitivity mouse hamster proteins The subject medical history immunological disorder , exclude seasonal allergic rhinitis/conjunctivitis , food allergy animal allergy The subject medical history thromboembolic event The subject HIV positive absolute CD4 count &lt; 200/mm3 The subject diagnose cardiovascular disease ( New York Heart Association ( NYHA ) class 14 ) The subject diagnose insulindependent diabetes mellitus The subject acute illness ( e.g . influenza , flulike syndrome , allergic rhinitis/conjunctivitis ) The subject diagnose liver disease , evidence , limited , follow : serum ALT three time upper limit normal , hypoalbuminemia , portal vein hypertension ( e.g . presence otherwise unexplained splenomegaly , history esophageal varix ) The subject diagnose renal disease , serum creatinine level &gt; = 2 mg/dL In judgment investigator , subject another clinically significant concomitant disease ( e.g . uncontrolled hypertension , diabetes type II ) may pose additional risk subject The subject treat immunomodulatory drug , exclude topical treatment ( e.g . ointment , nasal spray ) within 30 day enrollment The subject treat drug know induce thrombotic thrombocytopenic purpura ( TTP ) ( e.g . Adenosine diphosphate ( ADP ) receptor inhibitor ( Clopidogrel , Ticlopidine ) ) within 60 day enrollment The subject receive anticipates receive another investigational and/or interventional drug within 30 day enrollment The subject lactate female The subject history drug alcohol abuse within last 5 year The subject progressive fatal disease and/or life expectancy le 3 month The subject identify investigator unable unwilling cooperate study procedures The subject suffers mental condition render him/her unable understand nature , scope possible consequence study and/or evidence uncooperative attitude Subject prison compulsory detention regulatory and/or juridical order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>